RecruitingPhase 2NCT07721025

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

A Phase 2, Multicenter, Open-label, Randomized, Controlled Study of LX2006 Gene Therapy in Participants With Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)

Sponsor

Lexeo Therapeutics

Enrollment

26 participants

Start Date

Jun 25, 2026

Study Type

INTERVENTIONAL

Conditions

Friedreich Ataxia Cardiomyopathy, Secondary

Summary

The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).

Eligibility

Min Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying LX2006 and Usual Care for people with cardiomyopathy, secondary and friedreich ataxia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICLX2006

Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

OTHERUsual Care

Cohort 1: Participants ≥16 years of age with FA-CM Participants will receive usual care for 26 weeks before receiving treatment with LX2006 (single crossover).